Table 3.
AGREE-REX standardized domain scores: CPGs by SEOM (n= 28)
| Guidelines [references] | Domain (%) | Mean score (SD) | ||
|---|---|---|---|---|
| D1 Clinical applicability |
D2 Values and preferences |
D3 Implementability |
||
| Breast (early stage) [23, 55] | 77.8 | 45.8 | 65.5 | 63.0 (0.2) |
| Breast (advanced) [27, 60] | 72.2 | 30.6 | 51.7 | 41.3 (0.1) |
| Colorectal (metastasic) [33, 66] | 85.2 | 54.2 | 20.7 | 53.4 (0.0) |
| Colorectal (hereditary) [39, 65] | 96.3 | 25.0 | 38.0 | 53.1 (0.4) |
| Endometrial [25, 57, 58] | 35.2 | 19.4 | 27.6 | 27.4 (0.1) |
| Gastrointestinal sarcomas [48] | 92.6 | 12.5 | 0.0 | 35.0 (0.5) |
| Glioblastoma [45] | 98.2 | 27.8 | 13.8 | 46.6 (0.5) |
| Glioma (anaplasic) [24, 56] | 64.8 | 5.6 | 34.5 | 35.0 (0.3) |
| Glioma (low grade) [54, 83] | 87.0 | 34.7 | 58.6 | 60.1 (0.3) |
| Head and neck [46, 84, 85] | 59.3 | 26.4 | 58.6 | 48.1 (0.2) |
| Hepatocellular [31, 62, 63] | 92.6 | 56.9 | 82.8 | 77.4 (0.2) |
| Kidney [40, 86–88] | 77.8 | 26.4 | 44.8 | 49.7 (0.3) |
| Lung (small cell) [30] | 88.9 | 29.1 | 31.0 | 49.7 (0.3) |
| Lung (non-small cell) [42, 89] | 64.8 | 9.7 | 0.0 | 24.8 (0.3) |
| Lymphoma (follicular non-Hodgkin) [49] | 70.4 | 45.8 | 62.1 | 59.4 (0.1) |
| Medulloblastoma [41] | 79.6 | 27.8 | 62.1 | 56.5 (0.3) |
| Melanoma [43, 90, 91] | 85.2 | 40.3 | 55.1 | 60.2 (0.2) |
| Mesothelioma [47] | 92.6 | 27.8 | 0.0 | 40.1 (0.5) |
| Nasopharynx [53, 92] | 75.9 | 29.2 | 62.1 | 55.7 (0.2) |
| Neuroendocrine [37, 93] | 64.8 | 19.4 | 41.4 | 41.9 (0.2) |
| Ovarian [50, 94, 95] | 94.5 | 37.5 | 17.2 | 49.7 (0.4) |
| Pancreatic and biliary [34, 96, 97] | 66.7 | 27.8 | 44.8 | 46.4 (0.2) |
| Prostate [36, 98–100] | 72.2 | 34.7 | 44.8 | 50.6 (0.2) |
| Rectal [26, 59] | 74.1 | 12.5 | 37.9 | 41.5 (0.3) |
| Sarcoma [28, 61] | 75.9 | 29.2 | 17.3 | 40.1 (0.3) |
| Thymic epithelial [51] | 75.9 | 27.8 | 69.0 | 57.6 (0.3) |
| Thyroid [32, 64] | 55.6 | 27.8 | 69.0 | 50.8 (0.2) |
| Urothelial bladder [35, 101, 102] | 87.0 | 18.1 | 27.6 | 44.2 (0.4) |
Domain 1 “Clinical applicability”: Items 1. Evidence, 2. Applicability to Target Users, 3. Applicability to Patients/Population; Domain 2 “Values and Preferences”: Items 4. Values and Preferences of Target Users, 5. Values and Preferences of Patients/Population, 6. Values and Preferences of Policy/Decision-makers, 7. Values and Preferences of Guideline Developers; Domain 3 “Implementability”: Items 8. Purpose, 9. Local application and Adoption.